Redeye initiates coverage of Intervacc, a veterinary vaccine company focused on infectious diseases in horses. Following a slower-than-expected commercial rollout and a series of equity issues, the share price has fallen significantly from previous highs. We believe the market underestimates the long-term sales potential of Strangvac, particularly in the US.
LÄS MER
